- Home
- BSTZ vs PGEN Comparison
BSTZ vs PGEN Comparison
Compare BSTZ & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BSTZ | PGEN |
|---|---|---|
| Founded | 2019 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.2B |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | BSTZ | PGEN |
|---|---|---|
| Price | $30.55 | $7.42 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $8.33 |
| AVG Volume (30 Days) | 172.7K | ★ 6.1M |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | ★ 8.31% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.71 | 0.03 |
| Revenue | N/A | ★ $230,981,000.00 |
| Revenue This Year | N/A | $1,115.92 |
| Revenue Next Year | N/A | $81.04 |
| P/E Ratio | ★ $42.59 | $242.67 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $20.69 | $2.99 |
| 52 Week High | $31.89 | $7.55 |
Technical Indicators
Market Signals| Indicator | BSTZ | PGEN |
|---|---|---|
| Relative Strength Index (RSI) | 53.66 | 67.89 |
| Support Level | $26.55 | $3.96 |
| Resistance Level | $30.75 | N/A |
| Average True Range (ATR) | 0.68 | 0.40 |
| MACD | -0.07 | 0.03 |
| Stochastic Oscillator | 34.93 | 95.38 |
Price Performance
Historical ComparisonAbout BSTZ BlackRock Science and Technology Term Trust of Beneficial Interest
BlackRock Science and Technology Trust II is a diversified, closed-end management investment company. Its investment objectives are to provide total return and income mainly through long-term capital appreciation. The Trust invests a majority of its total assets in equity securities issued by U.S. and non-U.S. science and technology companies in any market capitalization range, selected for their rapid and sustainable growth potential from the development, advancement, and use of science and/or technology. Its investment portfolio comprises securities of companies from various industries, such as semiconductors and semiconductor equipment, software, communications equipment, IT services, and entertainment, etc.
About PGEN Precigen Inc.
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.